Acellular dermal matrices consist of extracellular matrices derived from human or animal dermal tissue that have had all cellular components removed. They provide a scaffold for cellular infiltration and tissue regeneration when implanted at a wound site. Cells such as keratinocytes, fibroblasts, and endothelial cells can repopulate the scaffold and rebuild the dermal architecture. They serve as temporary templates that facilitate endogenous wound healing processes. An increasing number of patients suffering from chronic wounds, burns, and other injuries requiring tissue reconstruction has boosted demand for acellular dermal matrices.
The global Acellular Dermal Matrices Market is estimated to be valued at US$ 8.8 Bn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rising prevalence of diabetes and associated chronic wounds has emerged as a key growth driver for the market. It is estimated that about 15% of patients suffering from diabetes develop non-healing foot ulcers during their lifetime. Acellular dermal matrices enhance healing of these difficult-to-treat wounds by providing a scaffold for cellular in-growth and neo-vascularization. In addition, ongoing research in tissue engineering is focused on developing advanced regenerative matrices with enhanced wound healing properties. Efforts are underway to engineer matrices with microstructures, growth factors, and cells to better mimic the native tissue environment and induce faster healing. This is expected to expand the application scope of acellular dermal matrices.
Threat of new entrants: The threat of new entrants in the acellular dermal matrices market is low. Manufacturing of medical devices requires considerable capital investments and regulatory approvals which act as entry barriers for new players.
Bargaining power of buyers: The bargaining power of buyers is high. The market is dominated by a few global players and there are many product alternatives available. This gives buyers leverage to negotiate for lower prices.
Bargaining power of suppliers: The bargaining power of suppliers is moderate. The raw materials required are commoditized but the manufacturing process expertise acts as a differentiator.
Threat of new substitutes: The threat of new substitutes is moderate. Ongoing research has increased the adoption of regenerative tissue such as human acellular dermal matrix but they have usage limitations and higher costs.
Competitive rivalry: The competitive rivalry is high. The market is dominated by a few global players who compete aggressively on product quality, pricing and service offerings.
The Global Acellular Dermal Matrices Market Growth is expected to witness high over the forecast period supported by increasing usage in plastic surgeries and advancements in regenerative medicine. The global Acellular Dermal Matrices Market is estimated to be valued at US$ 8.8 Bn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030.
Regional analysis: North America dominates the market owing to rising cosmetic procedures, technological advancements and availability of favorable reimbursements. Asia Pacific is expected to grow at the fastest pace driven by expansion of healthcare infrastructure, rise in medical tourism and growing awareness.
Key players: Merck & Co., Inc. (Merck Animal Health), Ceva, Zoetis Services LLC, Boehringer Ingelheim International GmbH are some of the leading players in the global acellular dermal matrices market. The companies are focusing on new product launches and strengthening their distribution networks especially in developing regions to capitalize on high growth opportunities.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it